NCT03635827View on ClinicalTrials.gov

Xenon Inhalation for Treatment of Posttraumatic Stress Disorder

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

July 31, 2021

Conditions
Post Traumatic Stress Disorder
Interventions
COMBINATION_PRODUCT

NBTX-001 Xenon Inhaler

The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.

COMBINATION_PRODUCT

Placebo

The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.

Sponsors
All Listed Sponsors
lead

Nobilis Therapeutics Inc.

INDUSTRY

NCT03635827 - Xenon Inhalation for Treatment of Posttraumatic Stress Disorder | Biotech Hunter | Biotech Hunter